KRAS G12D Inhibitor QLC1101 clinical trials
Also written QLC1101.
How each study uses KRAS G12D Inhibitor QLC1101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KRAS G12D Inhibitor QLC1101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QLC1101
- 2
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
QL1203 (1) · QL2107 (1) · Iparomlimab/Tuvonralimab (1)
Studies
Open first, then newest update. How each study uses KRAS G12D Inhibitor QLC1101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy SubjectsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06980909Written as QLC1101
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT06949761Written as QLC1101+QL1203
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid TumorsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06403735Written as QLC1101